TOVX - Theriva Biologics Short-Term Debt to Capital

Symbol and logo of brand Synthetic Biologics (TOVX)

Market price action on GURU.Markets demonstrates the 0.04 metric, while Theriva Biologics, Inc. (TOVX) conducts independent clinical trials, excluding mergers. The business relies on the unique VCN-01 virus, which destroys the protective layer of pancreatic tumors. Additionally, Theriva Biologics, Inc. (TOVX) is developing partnerships with medical centers to jointly create innovative therapy methods for combating severe forms of colorectal cancer.

Current Liabilities to Capital: Synthetic Biologics (TOVX) for 04/28/2023 - 11/01/2026

Summary analytical data breakdowns for therivabio.com (TOVX)

- stock value and consensus price forecast:
Price Chart Synthetic Biologics|TOVX - Broker Consensus Forecast
- market capitalization statistics:
Market Capitalization Theriva Biologics Inc|TOVX - Real Price to Acquire Entire Company
- book capitalization information:
Net Assets per Single Share Theriva Biologics|TOVX - Total Stockholders' Equity|Market Value to Book Value Ratio therivabio.com|TOVX - Aggregate Company Assets
- issuer credit burden and liquidity indicators:
Debt to Equity Theriva Biologics, Inc.|TOVX - Long-Term Liabilities to Capital|Short-Term Debt to Capital Theriva Biologics|TOVX - Company Total Indebtedness|Debt to Book Value Theriva Biologics Inc|TOVX - Long-Term Debt|Company Current Liabilities Theriva Biologics|Quick Ratio therivabio.com
- company profitability and valuation multiples indicators:
TOVX - Net Financial Result
Initial company analysis:Synthetic Biologics TOVX
Signature product of therivabio.com

This indicator assesses the share of short-term liabilities within the equity structure to determine liquidity risk and the degree of dependence on borrowed funds; by analyzing the trend of short-term loans relative to equity, an investor can gauge debt management efficiency, which is critical for Theriva Biologics, Inc. (TOVX) when financing external clinical trials via outsourcing without creating redundant production capacities.

Competitors of Theriva Biologics, Inc. (TOVX)

Short-Term Debt to Equity ImmunityBio Corp (IBRX)|Immunocore Corp - Short-Term Debt to Capital Ratio|Short-Term Debt to Capital JANX (Janux Therapeutics)|RCUS - Short-Term Debt to Equity Ratio|ZYME - Short-Term Debt to Equity|Current Liabilities to Capital Tango Therapeutics Inc|Iovance (IOVA) - Short-Term Debt to Equity|IMTX (Immatics Biotechnologies) - Short-Term Debt to Equity|Short-Term Debt to Equity Xencor, Inc.|Current Liabilities to Capital compasstherapeutics.com CMPX|Short-Term Debt to Capital REPL|Lyell (LYEL) - Short-Term Indebtedness to Equity|Innate Pharma, S.A. - Short-Term Debt to Equity Ratio|Pyxis Oncology Inc. (PYXS) - Current Liabilities to Capital|CGEN: Short-Term Debt to Equity Ratio|Ratio of Short-Term Indebtedness to Capital IOBT (iobiotech.com)|STRO: Short-Term Debt to Capital|INKT - Short-Term Debt to Capital Coefficient|Short-Term Debt to Equity Werewolf Therapeutics Inc.|Short-Term Debt to Equity Ratio Immix (IMMX)|Short-Term Debt to Equity ALX Oncology (ALXO)|Short-Term Debt to Equity Ratio Cue Biopharma Inc. CUE|PDS Biotechnology Corporation - Short-Term Debt to Equity Ratio|Short-Term Debt to Capital Sonnet BioTherapeutics Holdings, Inc. SONN|MAIA - Short-Term Debt to Equity|LIMN (Liminatus) - Short-Term Debt to Capital Ratio|lavatherapeutics.com (LVTX) - Short-Term Debt to Equity|Current Liabilities to Capital nextcure.com (NXTC)|Short-Term Debt to Equity Ratio LPTX|INTS - Short-Term Indebtedness to Equity|Short-Term Debt to Equity Ratio SNSE (Sensei Biotherapeutics)|Short-Term Loans to Capital Ratio GRTS|Short-Term Debt to Capital KA (Kineta, Inc.)|Ratio of Short-Term Indebtedness to Capital NEXI|Turnstone Biologics Corporation - Short-Term Debt to Capital|Current Liabilities to Capital Vaccinex Inc.|Harpoon Tx (HARP) - Short-Term Debt to Equity